Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm trial of alectinib in pretreated RET-rearranged advanced non-small cell lung cancer
NL-OMON46669Phase 2Active, not recruiting
- Sponsor
- European Thoracic Oncology Platform
- Start
- May 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of alectinib in non-small cell lung cancer (NSCLC), sponsored by European Thoracic Oncology Platform. Primary endpoint: Best overall response per investigator. Started May 2019; status: active, not recruiting.
02
Drugs
alectinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON46669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46669.